ALECENSARO (alectinib) received approval from Health Canada as a monotherapy for the treatment of patients with anaplastic lymphoma kinase-positive, locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. The drug is marketed under the name Alecensa in the US. The drug, which...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
